Pluvicto approved for PSMA-positive metastatic castration-resistant prostate cancer
The U.S. Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for treatment of adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer ...
Apr 14, 2022
0
2